The origin of many diseases begins at the cellular level and involves multiple molecular interactions. However, previous methods have struggled to accurately observe changes in individual cells.
RNA sequencing has emerged as a powerful supplement to DNA sequencing for Mendelian disease diagnosis, but clinical translation of diagnostic RNA-seq has not been widely achieved. Researchers at ...
Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the ...
We validated a clinical bait-capture WTS assay using 78 solid tumor samples across diverse tissue types, including 59 with known fusions or oncogenic splice variants. Sensitivity was assessed against ...
Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
Caris Life Sciences, Inc. (NASDAQ:CAI) is one of the Best All-Time Low Stocks to Invest In Now. On February 24, Caris Life ...
Genetic variants that cause rare disorders may remain elusive even after expansive testing, such as exome sequencing. The diagnostic yield of genome sequencing, particularly after a negative ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results